Efficacy of Second-Line Pemetrexed-Carboplatin in EGFR-Activating Mutation-Positive NSCLC: Does Exon 19 Deletion Differ from Exon 21 Mutation?

BACKGROUND: It is unknown whether the outcomes of second-line pemetrexed-carboplatin chemotherapy administered after progression on gefitinib are dependent on type of EGFR mutation present at baseline. METHOD: Adult non-small-cell lung cancer patients, with exon 19 deletion or exon 21 L858R mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Amit, Noronha, Vanita, Patil, Vijay M., Chougule, Anuradha, Bhattacharjee, Atanu, Kumar, Rajiv, Goud, Supriya, More, Sucheta, Ramaswamy, Anant, Karpe, Ashay, Pande, Nikhil, Chandrasekharan, Arun, Goel, Alok, Talreja, Vikas, Mahajan, Abhishek, Janu, Amit, Purandare, Nilendu, Prabhash, Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672602/
https://www.ncbi.nlm.nih.gov/pubmed/29201462
http://dx.doi.org/10.1155/2017/8196434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5672602/
https://www.ncbi.nlm.nih.gov/pubmed/29201462
http://dx.doi.org/10.1155/2017/8196434

Ejemplares similares